Filana Therapeutics (FLNA) Q2 2024 earnings summary

Executive summary

• Reported Q2 2024 net income of $6.2 million, reversing a $26.4 million loss in Q2 2023, driven by a $65.1 million non-cash warrant gain and offset by a $40 million SEC loss contingency.

• Cash and cash equivalents totaled $207.3 million at June 30, 2024, with no debt.

• Both Phase 3 simufilam Alzheimer's trials (RETHINK-ALZ and REFOCUS-ALZ) are fully enrolled, with RETHINK data expected by year-end 2024 and REFOCUS mid-2025.

• Significant management changes in July 2024, including CEO and SVP Neuroscience resignations and appointment of a new Executive Chairman.

• Ongoing government investigations, lawsuits, and a $40 million legal loss contingency related to a potential SEC settlement.

Financial highlights

• Net income of $6.2 million in Q2 2024, compared to a net loss of $26.4 million in Q2 2023, due to a $65.1 million non-cash warrant gain.

• Cash and cash equivalents were $207.3 million as of June 30, 2024, up from $121.1 million at year-end 2023, bolstered by $123.6 million in net warrant exercise proceeds.

• R&D expenses were $15.2 million in Q2 2024, down from $25 million in Q2 2023 due to completion of Phase 3 enrollment.

• G&A expenses rose to $46.2 million from $3.8 million, mainly due to the $40 million SEC loss contingency and higher compensation/legal costs.

• Projected year-end 2024 cash balance between $117 million and $127 million.

Outlook and guidance

• Top-line data from the 52-week RETHINK-ALZ trial expected by end of 2024; REFOCUS-ALZ readout anticipated mid-2025.

• Net cash use in H2 2024 projected at $80–90 million, including the $40 million SEC loss contingency.

• Cash reserves are expected to fund operations through both Phase 3 trial completions and into 2026.

• R&D expenses expected to decrease modestly as Phase 3 enrollment is complete, partially offset by higher open-label extension enrollment and stock-based compensation.

• General and administrative expenses will remain elevated due to ongoing legal matters and executive hiring.